Literature DB >> 21307155

Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis.

Suhair Jabbar1, John Drury, John N Fordham, Harish K Datta, Roger M Francis, Stephen P Tuck.   

Abstract

BACKGROUND: Osteoprotegerin (OPG) and receptor activator of nuclear factor κ B ligand (RANKL) play a critical role in the regulation of bone turnover, but the relative importance of these two cytokines in the pathogenesis of postmenopausal osteoporosis is controversial. AIM: To investigate the relationship between circulating levels of OPG, RANKL, bone turnover and bone mineral density (BMD) in postmenopausal women.
METHODS: A cross-sectional study of 185 women with osteoporosis and 185 age- and sex-matched control subjects was undertaken. Measurements were made of plasma OPG, RANKL, interleukin-6 (IL-6), sex steroids, calciotropic hormones, biochemical markers of bone turnover, BMD and anthropometry. Health questionnaires were administered.
RESULTS: Plasma RANKL was significantly higher (p<0.0001) in women with osteoporosis (0.66±0.67 pmol/l) than in control subjects (0.37±0.38 pmol/l), as was plasma OPG (18.70±9.70 pmol/l in women with osteoporosis, 10.44±5.85 pmol/l in control subjects; p<0.0001). OPG/RANKL ratio was higher in women with osteoporosis (51.3) than in control subjects (36.6). The women with osteoporosis also had significantly higher biochemical markers of bone turnover, IL-6 and parathyroid hormone and lower 25-hydroxyvitamin D and oestradiol than the control subjects. Multiple regression analysis showed that lumbar spine and femoral neck BMD in postmenopausal women were best predicted by OPG and RANKL, giving an R(2) value of 15.5% and 14.9%, respectively.
CONCLUSIONS: This study indicates that the circulating levels of OPG and RANKL are inversely related to BMD and contribute to the development of osteoporosis in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307155     DOI: 10.1136/jcp.2010.086595

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  34 in total

Review 1.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

2.  A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.

Authors:  S Ermakov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2011-11-05       Impact factor: 4.507

3.  The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.

Authors:  José A Balsa; Christian Lafuente; Jesús M Gómez-Martín; Julio Galindo; Roberto Peromingo; Francisca García-Moreno; Gloria Rodriguez-Velasco; Javier Martínez-Botas; Diego Gómez-Coronado; Héctor F Escobar-Morreale; José I Botella-Carretero
Journal:  J Bone Miner Metab       Date:  2015-10-05       Impact factor: 2.626

4.  Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.

Authors:  Jennifer Hoy; Birgit Grund; Mollie Roediger; Kristine E Ensrud; Indira Brar; Robert Colebunders; Nathalie De Castro; Margaret Johnson; Anjali Sharma; Andrew Carr
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

5.  Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.

Authors:  J Coulson; L Bagley; Y Barnouin; S Bradburn; G Butler-Browne; H Gapeyeva; J-Y Hogrel; T Maden-Wilkinson; A B Maier; C Meskers; C Murgatroyd; M Narici; M Pääsuke; L Sassano; S Sipilä; N Al-Shanti; L Stenroth; D A Jones; J S McPhee
Journal:  Osteoporos Int       Date:  2017-06-05       Impact factor: 4.507

6.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

7.  Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.

Authors:  Hongyu Zhao; Weisong Cai; Shuai Li; Zuke Da; Hanxue Sun; Liang Ma; Yaoxin Lin; Debao Zhi
Journal:  Childs Nerv Syst       Date:  2013-04-05       Impact factor: 1.475

8.  Biochemical markers in the follow-up of the osteoporotic patients.

Authors:  Alessandro Terreni; Paola Pezzati
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30

9.  Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model.

Authors:  Ahmet Yardimci; Mehmet Ridvan Ozdede; Haluk Kelestimur
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

10.  Modelling osteomyelitis.

Authors:  Pietro Liò; Nicola Paoletti; Mohammad Ali Moni; Kathryn Atwell; Emanuela Merelli; Marco Viceconti
Journal:  BMC Bioinformatics       Date:  2012-09-07       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.